NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Follitropin alfa:生物相似藥的洞察(2020年)

Follitropin alfa- Biosimilar Insight, 2020

出版商 DelveInsight Business Research LLP 商品編碼 973901
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
Follitropin alfa:生物相似藥的洞察(2020年) Follitropin alfa- Biosimilar Insight, 2020
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

本報告提供生物相似藥:Follitropin alfa的相關調查,10家公司以上的企業和10項產品以上的成藥及開發平台藥物相關全面的洞察,含臨床、非臨床階段的產品的市售及開發平台的藥物簡介,各產品類型、階段、給藥途徑、分子類型的治療方法的評估,市場成長要素和障礙,競爭情形等資訊。

本報告記載的企業

  • Biocad
  • Finox Biotech
  • CinnaGen
  • Dong-A ST
  • Gema Biotech S.A.
  • MinaPharm Pharmaceuticals
  • IVFarma
  • Merck Serono
  • Teva Pharma
  • Theramex
  • AbbVie
  • Itero Biopharmaceuticals
  • Cadila Healthcare

本報告刊載主要的產品

  • Bemfola
  • Cinnal-F
  • DA-3801
  • Folitime
  • Follitropin-alpha
  • Ovaleap
  • Primapur

目錄

第1章 重要的洞察

第2章 概述

第3章 摘要整理

  • 概要
  • 生技藥品的基礎
  • 學名藥和生物相似藥
  • 生物相似藥的經濟學:低價格的承諾,實際的費用
  • 患者需要了解哪些有關生物相似藥的訊息

第4章 生物相似藥的法規預測

  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 其他地區
    • 巴西
    • 墨西哥
    • 阿根廷
    • 沙烏地阿拉伯

第5章 Follitropin alfa(參照產品:Gonal-F)

  • 藥物的簡介
  • 產品概要
  • 法規當局的認證和推出
  • 適應症
  • 作用機制
  • 投藥和管理
  • 劑量和優勢
  • 用量變更
  • 合成途徑
  • 藥理學
  • 藥效學
  • 藥物動力學
  • 副作用
  • 產品的概述
  • 開發里程碑

第6章 研究開發

  • 臨床試驗資訊
  • 安全性和有效性

第7章 Gonal-F生物相似藥:新機會

第8章 Follitropin alfa:生物相似藥的評估

  • 各產品類型的評估
  • 各給藥途徑的評估
  • 各分子類型的評估
  • 各銷售的評估

第9章 企業簡介

    • Finox Biotech
    • iVFarma

第10章 比較形勢:各企業

第11章 競爭情形

    • 概要
    • 市場佔有率分析
    • 競爭模式

第12章 市場成長要素

第13章 市場障礙

第14章 SWOT分析

第15章 附錄

  • 調查手法

第16章 參考文件

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

目錄

DelveInsight's, "Follitropin alfa- Biosimilar Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Follitropin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Follitropin alfa Understanding

Follitropin alfa: Overview

Gonal-f (follitropin alfa for injection) is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the α- and B-subunits. The α- and B-subunits have 92 and 111 amino acids, respectively, and their primary and tertiary structure are indistinguishable from those of human follicle stimulating hormone. Recombinant FSH production occurs in genetically modified Chinese Hamster Ovary (CHO) cells cultured in bioreactors. Purification by immunochromatography using an antibody specifically binding FSH results in a highly purified preparation with a consistent FSH isoform profile, and a high specific activity.

Follitropin alfa Biosimilars: Drugs Chapters

This segment of the Follitropin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Follitropin alfa Biosimilars: Marketed Drugs

  • Bemfola: Gedeon Richter

Bemfola is a medicine that contains the active substance follitropin alfa. It is used to treat the following groups: women who do not produce eggs and who do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs)

Further product details are provided in the report:

Follitropin alfa Biosimilars: Emerging Drugs

  • Primapur: IVFarma

IVFarma is developing Primapur for the treatment of Female infertility.

Further product details are provided in the report:

Follitropin alfa: Therapeutic Assessment

This segment of the report provides insights about the different Follitropin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Follitropin alfa

There are approx. 10+ key companies which are developing the therapies for Follitropin alfa.

  • Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like:

  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Follitropin alfa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Subcutaneous
  • Intravenous
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Follitropin alfa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Follitropin alfa biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follitropin alfa biosimilar drugs.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Follitropin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Follitropin alfa.

Follitropin alfa Biosimilars Report Insights

  • Follitropin alfa Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs

Follitropin alfa Biosimilar Report Assessment

  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Follitropin alfa Biosimilars?
  • How many Follitropin alfa biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follitropin alfa biosimilars therapeutics?
  • What are the clinical studies going on for Follitropin alfa biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Biocad
  • Finox Biotech
  • CinnaGen
  • Dong-A ST
  • Gema Biotech S.A.
  • MinaPharm Pharmaceuticals
  • IVFarma
  • Merck Serono
  • Teva Pharma
  • Theramex
  • AbbVie
  • Itero Biopharmaceuticals
  • Cadila Healthcare

Key Products

  • Bemfola
  • Cinnal-F
  • DA-3801
  • Folitime
  • Follitropin-alpha
  • Ovaleap
  • Primapur

Table of Contents

1. Key Insights

2. Follitropin alfa Biosimilars: Snapshot

3. Executive Summary

  • 3.1. Overview
  • 3.2. The Basics of Biologics.
  • 3.3. Biosimilars are not the Same as Generic Drugs
  • 3.4. Economics of Biosimilars - the Promise of Lower Prices, but at What Cost?
  • 3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

  • 4.1. North America
    • 4.1.1. US
    • 4.1.2. Canada
  • 4.2. Europe
  • 4.3. Asia Pacific
    • 4.3.1. China
    • 4.3.2. India
    • 4.3.3. Japan
    • 4.3.4. South Korea
    • 4.3.5. Australia
  • 4.4. Rest Of The World
    • 4.4.1. Brazil
    • 4.4.2. Mexico
    • 4.4.3. Argentina
    • 4.4.4. Saudi Arabia

More Countries would be added in the final report

5. Follitropin alfa (Reference Product: Gonal-F)

  • 5.1. Drug Profile
  • 5.2. Product Overview
  • 5.3. Regulatory Approvals and Launch
  • 5.4. Indications
  • 5.5. Mechanism of Action
  • 5.6. Dosage and Administration
  • 5.7. Dosage and Strengths
  • 5.8. Dose Modification
  • 5.9. Route of Synthesis
  • 5.10. Pharmacology
  • 5.11. Pharmacodynamics
  • 5.12. Pharmacokinetics
  • 5.13. Adverse Reactions
  • 5.14. Product Snapshot
  • 5.15. Development Milestones

6. Research and Development

  • 6.1. Clinical Trials Information
  • 6.2. Safety and Efficacy

7. Gonal-F Biosimilar: Emerging Opportunities

8. Follitropin alfa: Biosimilars Assessment

  • 8.1. Assessment by Product Type
  • 8.2. Assessment by Route of Administration
  • 8.3. Assessment by Molecule type
  • 8.4. Sales Assessment

9. Follitropin alfa Biosimilars Profiles: By Company

    • 9.1.1. Finox Biotech
      • 9.1.1.1. Bemfola: Finox Biotech
      • 9.1.1.1.1. Product Information
      • 9.1.1.1.2. Research and Development
      • 9.1.1.1.3. Other Development Activities
      • 9.1.1.1.4. General Description Table
    • 9.1.2. iVFarma
      • 9.1.2.1. Primapur: iVFarma
      • 9.1.2.1.1. Product Information
      • 9.1.2.1.2. Research and Development
      • 9.1.2.1.3. Other Development Activities
      • 9.1.2.1.4. General Description Table

More Companies and products would be added in the final report

10. Follitropin alfa Biosimilars: Comparative Landscape: By Company

11. Follitropin alfa Biosimilars: Competitive Landscape

    • 11.1.1. Overview
    • 11.1.2. Market Share Analysis
    • 11.1.3. Competitive Scenario
      • 11.1.3.1. Product Launches and approval
      • 11.1.3.2. Partnerships, Collaborations and Agreements
      • 11.1.3.3. Acquisitions
      • 11.1.3.4. Expansions
      • 11.1.3.5. Patent Expiration of Biologics

More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

  • 15.1. Research Methodology
    • 15.1.1. Coverage
    • 15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: Total Products for Follitropin alfa
  • Table 2: Late Stage Products
  • Table 3: Mid Stage Products
  • Table 4: Early Stage Products
  • Table 5: Pre-clinical & Discovery Stage Products
  • Table 6: Assessment by Product Type
  • Table 7: Assessment by Stage and Product Type
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Molecule Type
  • Table 11: Assessment by Stage and Molecule Type
  • Table 12: Inactive Products

List of Figures

  • Figure 1: Total Products for Follitropin alfa
  • Figure 2: Late Stage Products
  • Figure 3: Mid Stage Products
  • Figure 4: Early Stage Products
  • Figure 5: Preclinical and Discovery Stage Products
  • Figure 6: Assessment by Product Type
  • Figure 7: Assessment by Stage and Product Type
  • Figure 8: Assessment by Route of Administration
  • Figure 9: Assessment by Stage and Route of Administration
  • Figure 10: Assessment by Molecule Type
  • Figure 11: Assessment by Stage and Molecule Type
  • Figure 12: Inactive Products